293 related articles for article (PubMed ID: 29046930)
1. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.
Bowden SA; Adler BH
Osteoporos Int; 2018 Feb; 29(2):511-515. PubMed ID: 29046930
[TBL] [Abstract][Full Text] [Related]
2. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.
Whyte MP; Simmons JH; Moseley S; Fujita KP; Bishop N; Salman NJ; Taylor J; Phillips D; McGinn M; McAlister WH
Lancet Diabetes Endocrinol; 2019 Feb; 7(2):93-105. PubMed ID: 30558909
[TBL] [Abstract][Full Text] [Related]
3. Hypophosphatasia: From Diagnosis to Treatment.
Simon S; Resch H; Klaushofer K; Roschger P; Zwerina J; Kocijan R
Curr Rheumatol Rep; 2018 Sep; 20(11):69. PubMed ID: 30203264
[TBL] [Abstract][Full Text] [Related]
4. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
Kishnani PS; Rush ET; Arundel P; Bishop N; Dahir K; Fraser W; Harmatz P; Linglart A; Munns CF; Nunes ME; Saal HM; Seefried L; Ozono K
Mol Genet Metab; 2017 Sep; 122(1-2):4-17. PubMed ID: 28888853
[TBL] [Abstract][Full Text] [Related]
5. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Kishnani PS; Rockman-Greenberg C; Rauch F; Bhatti MT; Moseley S; Denker AE; Watsky E; Whyte MP
Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866
[TBL] [Abstract][Full Text] [Related]
6. Asfotase alfa therapy for children with hypophosphatasia.
Whyte MP; Madson KL; Phillips D; Reeves AL; McAlister WH; Yakimoski A; Mack KE; Hamilton K; Kagan K; Fujita KP; Thompson DD; Moseley S; Odrljin T; Rockman-Greenberg C
JCI Insight; 2016 Jun; 1(9):e85971. PubMed ID: 27699270
[No Abstract] [Full Text] [Related]
7. Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia.
Bowden SA; Adler BH
Osteoporos Int; 2018 Sep; 29(9):2155-2156. PubMed ID: 29967930
[No Abstract] [Full Text] [Related]
8. Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study.
Hofmann CE; Harmatz P; Vockley J; Högler W; Nakayama H; Bishop N; Martos-Moreno GÁ; Moseley S; Fujita KP; Liese J; Rockman-Greenberg C;
J Clin Endocrinol Metab; 2019 Jul; 104(7):2735-2747. PubMed ID: 30811537
[TBL] [Abstract][Full Text] [Related]
9. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.
Whyte MP; Rockman-Greenberg C; Ozono K; Riese R; Moseley S; Melian A; Thompson DD; Bishop N; Hofmann C
J Clin Endocrinol Metab; 2016 Jan; 101(1):334-42. PubMed ID: 26529632
[TBL] [Abstract][Full Text] [Related]
10. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.
Scott LJ
Drugs; 2016 Feb; 76(2):255-62. PubMed ID: 26744272
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-replacement therapy in perinatal hypophosphatasia: Case report and review of the literature.
Rougier H; Desrumaux A; Bouchon N; Wroblewski I; Pin I; Nugues F; Mornet E; Baujat G
Arch Pediatr; 2018 Oct; 25(7):442-447. PubMed ID: 30249491
[TBL] [Abstract][Full Text] [Related]
12. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia.
Hofmann C; Seefried L; Jakob F
Drugs Today (Barc); 2016 May; 52(5):271-85. PubMed ID: 27376160
[TBL] [Abstract][Full Text] [Related]
13. Effect of Asfotase Alfa on Muscle Weakness in a Japanese Adult Patient of Hypophosphatasia with Low ALP Levels.
Koyama H; Yasuda S; Kakoi S; Ohata Y; Shimizu Y; Hasegawa C; Hayakawa A; Akiyama T; Yagi T; Aotani D; Imaeda K; Ozono K; Kataoka H; Tanaka T
Intern Med; 2020 Mar; 59(6):811-815. PubMed ID: 31787692
[TBL] [Abstract][Full Text] [Related]
14. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia.
Rolvien T; Schmidt T; Schmidt FN; von Kroge S; Busse B; Amling M; Barvencik F
Bone; 2019 Oct; 127():67-74. PubMed ID: 31152801
[TBL] [Abstract][Full Text] [Related]
15. Impressive clinical improvement and disappearance of neuropathic pain in an adult patient with hypophosphatasia treated with asfotase alfa.
Zervou Z; Plooij R; van Velsen EFS; Timmermans RGM; Demirdas S; Zillikens MC
Eur J Med Genet; 2024 Apr; 68():104915. PubMed ID: 38325645
[TBL] [Abstract][Full Text] [Related]
16. Asfotase Alfa in Perinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia: A Guide to Its Use in the USA.
Scott LJ
BioDrugs; 2016 Feb; 30(1):41-8. PubMed ID: 26832358
[TBL] [Abstract][Full Text] [Related]
17. Enzyme Replacement Therapy in Hypophosphatasia.
Uçaktürk SA; Elmaogullari S; Ünal S; Gönülal D; Mengen E
J Coll Physicians Surg Pak; 2018 Sep; 28(9):S198-S200. PubMed ID: 30173697
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial.
Kitaoka T; Tajima T; Nagasaki K; Kikuchi T; Yamamoto K; Michigami T; Okada S; Fujiwara I; Kokaji M; Mochizuki H; Ogata T; Tatebayashi K; Watanabe A; Yatsuga S; Kubota T; Ozono K
Clin Endocrinol (Oxf); 2017 Jul; 87(1):10-19. PubMed ID: 28374482
[TBL] [Abstract][Full Text] [Related]
19. Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: Case report.
Freitas TQ; Franco AS; Pereira RMR
Medicine (Baltimore); 2018 Nov; 97(48):e13210. PubMed ID: 30508901
[TBL] [Abstract][Full Text] [Related]
20. A two-year follow-up of asfotase alfa replacement in a patient with hypophosphatasia: clinical, biochemical, and radiological evaluation.
Reis FS; Gomes DC; Arantes HP; Lazaretti-Castro M
Arch Endocrinol Metab; 2021 May; 64(5):623-629. PubMed ID: 34033304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
